| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 136, Issue 7 2478-2482, Copyright © 1986 by American Association of Immunologists
ARTICLES |
M Gowen and GR Mundy
Human peripheral blood cells, when cultured in vitro, release bone- resorbing factors, which have been called osteoclast-activating factors (OAF) but remain unidentified. We showed previously that a monocyte product, similar to interleukin 1 (IL 1), is a powerful stimulator of bone resorption in vitro. However, the possibility remained that other immune cell products may contribute to OAF activity. We have therefore tested three recombinant cytokines; IL 1, interleukin 2 (IL 2), and interferon-gamma (IFN-gamma) for their activity in a neonatal mouse bone resorption assay. We report here that purified recombinant murine IL 1 is a potent and powerful stimulator of bone resorption in vitro, active over a concentration range of 0.14 to 33 U/ml (1.3 X 10(-12) to 3.1 X 10(-10) M). IL 1-stimulated bone resorption was unaffected by cyclooxygenase inhibition but was inhibited by calcitonin and IFN- gamma. IL 2 had no effect on bone resorption.
This article has been cited by other articles:
|
|
 |
|
  S.L. Gaffen and G. Hajishengallis A New Inflammatory Cytokine on the Block: Re-thinking Periodontal Disease and the Th1/Th2 Paradigm in the Context of Th17 Cells and IL-17 J. Dent. Res., September 1, 2008; 87(9): 817 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U.H. Lerner Bone Remodeling in Post-menopausal Osteoporosis. J. Dent. Res., July 1, 2006; 85(7): 584 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Garcia-Perez, I. Noguera, C. Hermenegildo, A. Martinez-Romero, J.J. Tarin, and A. Cano Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice Hum. Reprod., April 1, 2006; 21(4): 880 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Bolton, A. A. Ionescu, K. M. Shiels, R. J. Pettit, P. H. Edwards, M. D. Stone, L. S. Nixon, W. D. Evans, T. L. Griffiths, and D. J. Shale Associated Loss of Fat-free Mass and Bone Mineral Density in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1286 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.A. Ionescu and E. Schoon Osteoporosis in chronic obstructive pulmonary disease Eur. Respir. J., November 2, 2003; 22(46_suppl): 64s - 75s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S W van der Merwe, J B van den Bogaerde, C Goosen, F F Maree, R J Milner, C M Schnitzler, A Biscardi, J M Mesquita, G Engelbrecht, D Kahn, et al. Hepatic osteodystrophy in rats results mainly from portasystemic shunting Gut, April 1, 2003; 52(4): 580 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hayashi, T. Kaneda, Y. Toyama, M. Kumegawa, and Y. Hakeda Regulation of Receptor Activator of NF-kappa B Ligand-induced Osteoclastogenesis by Endogenous Interferon-beta (INF-beta ) and Suppressors of Cytokine Signaling (SOCS). THE POSSIBLE COUNTERACTING ROLE OF SOCSs IN IFN-beta -INHIBITED OSTEOCLAST FORMATION J. Biol. Chem., July 26, 2002; 277(31): 27880 - 27886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz Changes in Proinflammatory Cytokine Activity after Menopause Endocr. Rev., February 1, 2002; 23(1): 90 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yoshii, H. Nishimura, T. Yoshikawa, S. Furudoi, A. Yoshioka, I. Takenono, Y. Ohtsuka, and T. Komori Therapeutic possibilities of long-term roxithromycin treatment for chronic diffuse sclerosing osteomyelitis of the mandible J. Antimicrob. Chemother., May 1, 2001; 47(5): 631 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, B. Boyce, M. Zhao, and G. Gutierrez Stimulation of Bone Formation in Vitro and in Rodents by Statins Science, December 3, 1999; 286(5446): 1946 - 1949. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Traianedes, M. R. Dallas, I. R. Garrett, G. R. Mundy, and L. F. Bonewald 5-Lipoxygenase Metabolites Inhibit Bone Formation in Vitro Endocrinology, July 1, 1998; 139(7): 3178 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ghazali, V. Fuentes, C. Desaint, P. Bataille, A. Westeel, M. Brazier, L. Prin, and A. Fournier Low Bone Mineral Density and Peripheral Blood Monocyte Activation Profile in Calcium Stone Formers with Idiopathic Hypercalciuria J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koeller, T. D. Brown, K. Beougher, J. Golando, E. M. Bonnem, and D. D. VonHoff A phase I trial of recombinant gamma interferon administered intravenously on a daily x 5 schedule Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 22 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 L. L. Key, R. M. Rodriguiz, S. M. Willi, N. M. Wright, H. C. Hatcher, D. R. Eyre, J. K. Cure, P. P. Griffin, and W. L. Ries Long-Term Treatment of Osteopetrosis with Recombinant Human Interferon Gamma N. Engl. J. Med., June 15, 1995; 332(24): 1594 - 1599. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
